4-(6-nitro-1H-benzo[d]imidazol-2-yl)benzoic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 4-(6-nitro-1H-benzo[d]imidazol-2-yl)benzoic acid
• 英文别名: 4-(5-nitro-1H-benzimidazol-2-yl)benzoic acid；4-(6-nitro-1H-benzimidazol-2-yl)benzoic acid
• 化学式: C₁₄H₉N₃O₄
• 分子量: 283.243
• InChiKey: HTAQJKNAKWJIAV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  112
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-(6-nitro-1H-benzo[d]imidazol-2-yl)benzoic acid 在 palladium on activated charcoal 吡啶 、 氢气 、 N,N'-羰基二咪唑 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 36.0h， 生成 N-[2-[4-(cyclohexylcarbamoyl)phenyl]-3H-benzimidazol-5-yl]adamantane-1-carboxamide
  参考文献：
  名称：

  取代的2-苯基-苯并咪唑衍生物：抑制过敏关键标志物的新型化合物。

  摘要：

  传统上，过敏和哮喘的药物治疗重点放在过敏级联反应的效应分子上，而忽略了在其发展中起早期作用的靶标。由于IgE对特应性疾病的扩展至关重要，因此我们确定并扩展了IgE反应的2-（取代苯基）-苯并咪唑抑制剂的新家族。药理活性取决于完整的苯基苯并咪唑-双酰胺主链，并通过存在由双环烷基或脂族和卤素取代的芳族基团组成的亲脂性端基来优化药理活性。这些化合物还抑制T细胞中的IL-4和IL-5应答以及B细胞上的CD23表达，其效力与其抑制IgE相似。

  DOI：

  10.1016/j.ejmech.2006.03.014
• 作为产物：
  描述：

  2-(4-cyanophenyl)-5-nitrobenzimidazole 在 sodium hydroxide 作用下， 生成 4-(6-nitro-1H-benzo[d]imidazol-2-yl)benzoic acid
  参考文献：
  名称：

  Benzimidazol-2-yl or benzimidazol-2-ylthiomethyl benzoylguanidines as novel Na+/H+ exchanger inhibitors, synthesis and protection against ischemic-reperfusion injury

  摘要：

  A novel series of benzimidazol-2-yl or benzimidazol-2-ylthiomethyl benzoylguanidines were designed and synthesized as Na+/H(+)exchanger inhibitors. Most of them were found to inhibit NHE1-mediated platelet swelling in a concentration-dependent manner, and to have significant cardioprotective effect against myocardial ischemic-reperfusion injury, among which compounds 10a and 34 were more potent than cariporide in both in vivo and in vitro tests. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.02.035

文献信息

• Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production
  申请人：Makovec Francesco

  公开号：US20050197331A1

  公开（公告）日：2005-09-08

  Heterocyclic amidines with anti-inflammatory and analgesic activity that inhibit nitrogen oxide production, of formula (I): in which: G 1 and G 2 are hydrogen, halogen, hydroxyl, C 1 -C 4 alkoxy, C 1 -C 4 alkyl, and an amidino substituent of formula Q, provided that, for each compound of formula (I), only one of the two substituents G 1 or G 2 is an amidino substituent of formula Q: and in which the substituents W, Y and X are combined to form 9- or 10-membered bicyclic heteroaromatic derivatives containing up to 2 hetero atoms in the same ring; and Z is an aryl or heteroaryl group, a linear or branched C 1 -C 6 alkyl or alkenyl chain, a C 1 -C 4 alkyl-aryl group or a C 1 -C 4 alkyl-heteroaryl group.

  含有抗炎和镇痛活性、抑制氮氧化物产生的杂环胺基化合物，化学式（I）如下：其中：G1和G2为氢、卤素、羟基、C1-C4烷氧基、C1-C4烷基和式为Q的胺基取代基，但对于化合物的每个化学式（I），G1或G2中仅有一个是式为Q的胺基取代基；其中取代基W、Y和X结合形成含有最多2个杂原子的同一环中的9-或10-成员双环杂芳衍生物；Z为芳基或杂芳基团、线性或支链状的C1-C6烷基或烯基链、C1-C4烷基-芳基团或C1-C4烷基-杂芳基团。
• Synthesis and Antimicrobial Activity of Some Novel 2-[4-(Substituted Piperazin-/Piperidin-1-ylcarbonyl)phenyl]-1<i>H</i>-benzimidazole Derivatives
  作者：Canan Kus、Fatma Sözüdönmez、Nurten Altanlar

  DOI：10.1002/ardp.200800084

  日期：2009.1

  In this study, we report the synthesis and antimicrobial evaluation of several new 4‐(1H‐benzimidazol‐2‐yl)benzamides (11–30) and 5‐chloro‐1‐(p‐fluorobenzyl)‐2‐4‐[(4‐methylpiperazin‐1‐yl)carbonyl]phenyl}‐1H‐benzimidazole (33). Compound 20 exhibited the best antibacterial activity with MIC value of 6.25 μg/mL against Staphylococcus aureus and methicillin‐resistant Staphylococcus aureus (MRSA). Significant

  在这项研究中，我们报告了几种新的 4-(1H-苯并咪唑-2-基)苯甲酰胺 (11-30) 和 5-氯-1-(对氟苄基)-2-4-[ (4-甲基哌嗪-1-基)羰基]苯基}-1H-苯并咪唑 (33)。化合物20对金黄色葡萄球菌和耐甲氧西林金黄色葡萄球菌（MRSA）表现出最佳抗菌活性，MIC值为6.25 μg/mL。化合物 13、14、18、19 和 33 具有显着的抗真菌活性，MIC 值为 3.12 μg/mL，与氟康唑接近。
• Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
  申请人：——

  公开号：US20020132808A1

  公开（公告）日：2002-09-19

  The present invention is directed to small molecule inhibitors of the IgE response to allergens, which are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic. This invention also relates to benzimidazole molecules that are cellular proliferation inhibitors and thus are useful as anticancer agents.

  本发明涉及针对过敏原的IgE反应的小分子抑制剂，可用于治疗过敏和/或哮喘或任何IgE致病的疾病。本发明还涉及苯并咪唑分子，这些分子是细胞增殖抑制剂，因此可用作抗癌剂。
• [EN] BENZIMIDAZOLE COMPOUNDS FOR MODULATING IGE AND INHIBITING CELLULAR PROLIFERATION<br/>[FR] COMPOSES DE BENZIMIDAZOLE MODULATEURS DE L'IGE ET INHIBITEURS DE LA PROLIFERATION CELLULAIRE
  申请人：AVANIR PHARMACEUTICALS

  公开号：WO2002072090A1

  公开（公告）日：2002-09-19

  The present invention is directed to small molecule inhibitors of the IgE response to allergens, which are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic. This invention also relates to benzimidazole molecules that are cellular proliferation inhibitors and thus are useful as anticancer agents.

  本发明涉及小分子抑制剂，用于抑制对过敏原的IgE反应，并可用于过敏症和/或哮喘或任何IgE为病原的疾病的治疗。本发明还涉及苯并咪唑分子，它们是细胞增殖抑制剂，因此可用作抗癌剂。
• BENZIMIDAZOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
  申请人：Sircar C. Jagadish

  公开号：US20070202133A1

  公开（公告）日：2007-08-30

  The present invention is directed to small molecule inhibitors of the IgE response to allergens, which are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic. This invention also relates to benzimidazole molecules that are cellular proliferation inhibitors and thus are useful as anticancer agents.

  本发明涉及小分子抑制剂，可抑制IgE对过敏原的反应，适用于过敏和/或哮喘或任何IgE致病的疾病的治疗。本发明还涉及苯并咪唑分子，它们是细胞增殖抑制剂，因此可用作抗癌剂。